Loading…
Japanese cosmetics company operating the direct-sales Pola brand and the mail-order/D2C Orbis skincare brand.
Japanese cosmetics company operating the direct-sales Pola brand and the mail-order/D2C Orbis skincare brand.
Pola sells through a force of commissioned beauty consultants and its own shops, so the consultant's skill rather than store traffic drives sales. Orbis sells directly to consumers by mail order and online, with no retailer in between.
In one line: Japan's Avon (direct sales) combined with a D2C skincare brand like Proactiv.
Moat: narrow (brand, distribution). Established direct-sales consultant network (Pola) plus a distinct D2C skincare brand (Orbis).
Headquarters: Tokyo, Japan · Founded: 1929 · Employees: 3,898
Size Pola Orbis (4927.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $1.96B, the 491st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,396 on 6 Nov 2026.
Performance Over six months the shares gained 7.9%, against -4.2% for the median peer and +1.8% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 0.9% over the last twelve months (peer median +3.7%); the operating margin is 10.2% (peer median 9.8%).
Valuation It trades at 28.8× forward earnings against a peer median of 21.0× (5th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥171B | ¥170B | ¥170B | ¥173B | ¥166B |
| Revenue growth | — | 0% | -2% | +4% | — |
| Gross profit | ¥139B | ¥132B | ¥132B | ¥136B | ¥128B |
| EBITDA | ¥25.6B | ¥23.9B | ¥22.2B | ¥23.8B | ¥21.4B |
| Net income | ¥11.4B | ¥9.47B | ¥9.29B | ¥9.66B | ¥11.4B |
| Free cash flow | n/a | ¥15.3B | ¥18.0B | ¥2.06B | ¥7.83B |
| Capital expenditure | n/a | ¥6.92B | ¥12.5B | ¥16.7B | ¥11.8B |
| Total debt | ¥33.0M | ¥1.60B | ¥2.12B | ¥1.69B | ¥1.88B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pola Orbis 4927.T | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% |
| KOSE 4922.T | $2.16B | +7% | +3% | 4% | 27.2× | n/a |
| Shiseido 4911.T | $9.52B | +20% | +5% | 4% | 32.8× | 17.5% |
| Noevir 4928.T | $977M | +3% | +1% | 16% | 19.4× | -4.8% |
| Kao 4452.T | $21.8B | +33% | +6% | 10% | 24.4× | 1.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4927.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.0% | +2.4% | 7th highest of 21 |
| 6-month return | +7.9% | -4.2% | 7th highest of 21 |
| Distance from 52-week high | -4.6% | -29.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +0.9% | +3.7% | 8th lowest of 21 |
| Operating margin | 10.2% | 9.8% | 10th highest of 21 |
| Forward P/E | 28.8× | 21.0× | 5th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -3.1% | 4.5% | 5th least demanding of 17 |
| Growth delivered (Del g) | -0.7% | +6.5% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | -2.4 pp | -2.5 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +7.0 pp | +5.3 pp | 8th highest of 21 |
| EV / EBITDA | 9.7× | 12.3× | 3rd cheapest of 12 |
| Net debt / EBITDA | -2.4× | -0.6× | 5th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $1.88B | -15% | -2% | -2% | 93.6× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% | +15.3% |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| Emami EMAMILTD.NS | India | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% | +5.6% |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% | -2.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.58B | -30% | +28% | 20% | 22.5× | 8.7% | +3.6% |
| AMOREPACIFIC 002790.KS | South Korea | $1.55B | -3% | +9% | 9% | 8.4× | -17.9% | -1.3% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| Intercos ICOS.MI | Italy | $1.50B | +16% | -5% | 9% | 19.5× | 4.5% | +11.5% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |